, /PRNewswire/ -- (DoH), the regulator of the healthcare sector, signed a second Memorandum of Understanding (MoU) with the Perelman School of Medicine at the ("Penn Medicine") to expand partnership in education, research and innovation programmes. Both parties will further collaborate on translational research ecosystem development, as well as launch innovative collaborative research involving "second labs" that leverage and build capabilities in and at Penn Medicine in , USA in leading-edge areas of science. The MoU has been signed by Dr.
, Executive Director of the Research and Innovation Centre at DoH and , Chief Operating Officer and Lead for Global Clinical Programmes, at Perelman School of Medicine at Penn Medicine. Through this MoU, DoH and Penn Medicine seek to design and develop a translational medicine ecosystem based on . In addition, the MoU seeks to explore the potential of launching two multi-year collaborative research programmes.
One focuses on the expanded application of artificial intelligence to identify new potential antibiotics. The other focuses on longitudinal follow-up and genetic analysis of people with Alzheimer's in that will facilitate cross-population comparative analysis and unique attributes that ultimately enable global prevention and early diagnosis. With the aim of bridging the gap between preliminary research and practical applications in medical practices, translational research seeks to translate research discoveries from laboratory findi.
